These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30356251)

  • 1. Role of economic evidence in coverage decision-making in South Korea.
    Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM
    PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation on the first 2 years of the positive list system in South Korea.
    Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
    Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different policy outcomes of the new drugs and currently listed drugs under the positive list system in South Korea.
    Lee EK; Kim BY; Lim JY; Park MH
    Value Health; 2012; 15(1 Suppl):S100-3. PubMed ID: 22265054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug reimbursement decision-making in Thailand, China, and South Korea.
    Ngorsuraches S; Meng W; Kim BY; Kulsomboon V
    Value Health; 2012; 15(1 Suppl):S120-5. PubMed ID: 22265058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
    Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
    Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
    Cho E; Yoo SL; Kang Y; Lee JH
    Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 15. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.